CALIPER LIFE SCIENCES TO ACQUIRE XENOGEN
Caliper Life Sciences, Inc., a leading provider of products and services for
drug discovery research, and Xenogen Corporation, a maker of advanced imaging
systems including instruments, biological solutions and software designed to
accelerate drug discovery and development, today announced their definitive
agreement to merge. Under the agreement, Caliper will issue common stock and
warrants, currently valued at approximately $80 million, in exchange for all
of Xenogen's equity securities outstanding at the closing.